非小细胞肺癌患者肝细胞生长因子受体和表皮生长因子受体及间变性淋巴癌激酶基因异常与临床病理特征的关系

Relationship between hepatocyte growth factor receptor,epidermal growth factor receptor and anaplastic lymphoma kinase gene abnormalities and clinicopathological features in patients with non-small cell lung cancer

目的分析非小细胞肺癌(NSCLC)患者肝细胞生长因子受体(c-Met)、表皮生长因子受体(EGFR)和间变性淋巴癌激酶(ALK)基因异常与临床病理特征的关系。方法回顾性分析2021年1—12月新钢中心医院收治的152例NSCLC患者的临床资料,取患者组织标本,采用荧光原位杂交技术检测c-Met基因扩增情况,采用聚合酶链扩增反应及直接测序法检测EGFR基因突变情况,采用实时荧光定量PCR检测ALK基因重排情况。分析c-Met基因扩增、EGFR基因突变和ALK基因重排与患者临床病理特征的关系。结果152例NSCLC患者中,c-Met基因扩增7例,阳性率为4.61%;EGFR基因突变48例,突变率为31.58%;ALK基因重排8例,重排率为5.26%。c-Met基因扩增阳性与阴性患者、ALK基因重排与无重排患者性别、年龄、临床分期、吸烟史、肿瘤位置、病理类型比较差异无统计学意义。EGFR基因突变与无突变患者性别、年龄、病理类型比较差异有统计学意义(P<0.05),其中EGFR基因突变患者以女性、年龄<70岁、腺癌占比较高。结论c-Met基因扩增及ALK基因重排与患者临床病理特征无关,而EGFR基因突变与患者性别、年龄及病理类型密切相关。

Objective To analyze the relationship between gene abnormalities of hepatocyte growth factor receptor(c-Met),epidermal growth factor receptor(EGFR)and anaplastic lymphoma kinase(ALK)gene abnormalities and clinicopathological features in patients with non-small cell lung cancer(NSCLC).Methods The clinical data of 152 patients with NSCLC admitted to Xingang Central Hospital from January to December 2021 were retrospectively analyzed,tissue specimens were taken from patients,and c-Met gene amplification was detected by fluorescence in situ hybridization,EGFR gene mutation was detected by polymerase chain amplification reaction and direct sequencing,and ALK gene rearrangement was detected by real-time fluorescence quantitative PCR.The relationship between c-Met gene amplification,EGFR gene mutation and ALK gene rearrangement and clinicopathological features of patients was analyzed.Results Among 152 patients with NSCLC,there were 7 cases of c-Met gene amplification,the positive rate was 4.61%;48 cases of EGFR gene mutation,the mutation rate was 31.58%;8 cases of ALK gene rearrangement,the rearrangement rate was 5.26%.There were no statistical difference in gender,age,clinical stage,smoking history,tumor location,pathological type between c-Met gene amplification positive and negative patients,and between ALK rearrangement and non-rearrangement patients.There were significant differences in gender,age and pathological types between EGFR gene mutation and non-mutation patients(P<0.05),and the proportion of female,age<70 years old and adenocarcinoma was higher in patients with EGFR gene mutation.Conclusion c-Met gene amplification and ALK gene rearrangement were not associated with clinicopathological features of patients,while EGFR gene mutation was closely associated with patient gender,age and pathological type of patients.